Abstract: The present invention provides an antibody for detecting mesothelioma and an antibody having high specificity to mesothelioma and high sensitivity thereto. The present invention also provides a method of diagnosis of mesothelioma by using the antibody, a reagent containing the antibody for use in diagnosis of mesothelioma, and a kit comprising the antibody for use in diagnosis of mesothelioma. Further, the present invention provides a marker for use in diagnosis of mesothelioma. Furthermore, the present invention provides a pharmaceutical composition containing the antibody according to the present invention or an antigen-binding fragment thereof for use in treatment of mesothelioma. An antibody that binds to a glycosylated HEG1 protein obtained from mesothelioma.

Abstract: One embodiment of this invention is a method for confirming expression of the PRDM14 gene from blood or lymphatic fluid collected from a subject by: (1) detecting PRDM14 positive CTC which expresses the PRDM14 gene; or (2) measuring the concentration of at least one protein selected from the group consisting of leptin receptor (LEPR), macrophage-derived chemokine (MDC) and gamma-interferon (IFN?).

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: A technique is provided which enables simple and low-cost purification of biologically active proteins by means of a conjugate of a target substance capturing molecule and a protein which comprises the amino acid sequence in SEQ ID NO:1, or a protein which comprises the amino acid sequence obtained by deleting, substituting or adding one or multiple amino acids in the amino acid sequence in SEQ ID NO: 1 and which has binding activity to a compound having —OH or —OR1 [R1 represents a hydrogen atom, an alkyl group or —PO3H2].

Abstract: The present invention relates to a method for detecting of a mutant DNA using a probe, comprising: (1) contacting a sample containing a single-stranded DNA which has a substituted nucleotide, a deleted nucleotide region, or an inserted nucleotide region (mutant-type DNA), or/and a wild-type single-stranded DNA (wild-type DNA) corresponding thereto with the probe which hybridizes with both single-stranded DNA, to form a hybrid with the mutant-type DNA (mutant-type hybrid) or/and a hybrid with a wild-type DNA (wild-type hybrid), wherein at least one of the obtained mutant-type hybrid and wild-type hybrid has the stem structure; (2) separating the obtained mutant-type hybrid or/and wild-type hybrid by electrophoresis on the basis of presence or absence of the stem structure or difference in the stem structure; and (3) detecting the presence or absence of the mutant-type DNA in the sample.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: A nucleic acid molecule that can bind to HMGB1 protein and applications thereof are provided. A nucleic acid molecule having a dissociation constant for HMGB1 protein of 5×10?7 or less can be used as the nucleic acid molecule that can bind to HMGB1 protein. The HMGB1 binding nucleic acid molecule can bind to HMGB1 protein that is known to be a cause of diseases such as cancer and inflammation, and it is therefore possible to obtain an effect to prevent and an effect to treat such diseases by allowing the HMGB1 binding nucleic acid molecule to bind to HMGB1 protein in a living body.

Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.

Abstract: The present invention provides a nucleic acid molecule capable of binding to c-Met as a substance that can be used for clarification of the pathogenic mechanism of diseases caused by c-Met, diagnosis and treatment of the diseases, and the like, and also the use thereof. The c-Met binding nucleic acid molecule of the present invention is any one of the following nucleic acid molecules (A1), (A2), (B1), and (B2).

Abstract: A method of recovering volatile organic matter such as fuels and organic solvents from a gas or gas mixture containing the organic matter, characterized by subjecting a gas or gas mixture, having diffused thereinto sparingly water-soluble or water-insoluble volatile organic matter in the form of vapor, mist and/or small droplets, to a two-step capturing treatment wherein the gas or gas mixture is first brought into gas-liquid contact with an aqueous capturing system capable of dissolving the volatile organic matter thereby capturing the organic matter in the form dissolved in the aqueous system and then the organic matter-containing aqueous system is brought into liquid-liquid contact with a non-volatile organic liquid, immiscible with the aqueous system such that the organic matter migrates from the aqueous system into the organic liquid, and thereafter recycling the aqueous capturing system to the first step of the two-step capturing treatment, while recovering the volatile organic matters from the non-vola

Abstract: A new and distinct variety of greenhouse rose plant which originated as a sport of the variety `Sonia` (U.S. Plant Pat. No. 3,095) and is particularly distinguished by the very light pink coloration of the outer petals of the mature flower which gives it a generally Neyron Rose appearance except for the lower inside portion of the petals at the center of the fully opened bloom which contrasts considerably with respect to the Porcelain Rose and Begonia Rose coloration of the parent plant. This new rose plant variety blooms continuously and profusely the year around under greenhouse conditions with large flowers carried on sturdy, upright stems and with a flower peduncle having a length of about twelve centimeters, the blooms being long lasting on the plant and having a moderate lasting quality as a cut flower. The plant itself has a vigorous and upright growth habit with a free branching character and abundant foliage.